Safety and efficacy of daratumumab-based regimens in elderly (≥75 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR.

被引：2
|
作者：
Mateos, Maria-Victoria
Spencer, Andrew
Nooka, Ajay K.
Pour, Ludek
Weisel, Katja C.
Cavo, Michele
Laubach, Jacob
Cook, Gordon
Iida, Shinsuke
Benboubker, Lotfi
Usmani, Saad Zafar
Yoon, Sung-Soo
Bahlis, Nizar J.
Chiu, Christopher
Schecter, Jordan Mark
Wu, Kaida
Qin, Xiang
Soong, David
Dimopoulos, Meletios A.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.8033
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8033
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Therapeutic Outcomes of Relapsed-Refractory Multiple Myeloma Patients with 1q21+Treated with Daratumumab-Based Regimens: A Retrospective Analysis
    Parrondo, Ricardo D.
    Gardner, Lindsay Brooke
    Moustafa, Mohamad Alhaj
    Roy, Vivek
    Sher, Taimur
    Rasheed, Ahsan
    Warsame, Rahma M.
    Larsen, Jeremy T.
    Gonsalves, Wilson I.
    Kourelis, Taxiarchis
    Kapoor, Prashant
    Fonseca, Rafael
    Chanan-Khan, Asher
    Ailawadhi, Sikander
    BLOOD, 2022, 140 : 7237 - 7238
  • [42] Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR
    Weisel, K.
    Palumbo, A.
    Chanan-Khan, A.
    Nooka, A. K.
    Spicka, I.
    Masszi, T.
    Beksac, M.
    Hungria, V.
    Munder, M.
    Mateos, M-V.
    Mark, T. M.
    Spencer, A.
    Qi, M.
    Schecter, J.
    Amin, H.
    Qin, X.
    Deraedt, W.
    Ahmadi, T.
    Sonneveld, P.
    ANNALS OF ONCOLOGY, 2016, 27
  • [43] Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study
    Suzuki, Kenshi
    Dimopoulos, Meletios A.
    Takezako, Naoki
    Okamoto, Shinichiro
    Shinagawa, Atsushi
    Matsumoto, Morio
    Kosugi, Hiroshi
    Yoon, Sung-Soo
    Huang, Shang-Yi
    Qin, Xiang
    Qi, Ming
    Iida, Shinsuke
    BLOOD CANCER JOURNAL, 2018, 8
  • [44] Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study
    Kenshi Suzuki
    Meletios A. Dimopoulos
    Naoki Takezako
    Shinichiro Okamoto
    Atsushi Shinagawa
    Morio Matsumoto
    Hiroshi Kosugi
    Sung-Soo Yoon
    Shang-Yi Huang
    Xiang Qin
    Ming Qi
    Shinsuke Iida
    Blood Cancer Journal, 8
  • [45] Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma
    Facon, Thierry
    Niesvizky, Ruben
    Mateos, Maria-Victoria
    Siegel, David
    Rosenbaum, Cara
    Bringhen, Sara
    Weisel, Katja
    Ho, P. Joy
    Ludwig, Heinz
    Kumar, Shaji
    Wang, Kenneth
    Obreja, Mihaela
    Yang, Zhao
    Klippel, Zandra
    Mezzi, Khalid
    Goldrick, Amanda
    Tekle, Christina
    Dimopoulos, Meletios A.
    BLOOD ADVANCES, 2020, 4 (21) : 5449 - 5459
  • [46] Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor
    Lentzsch, Suzanne
    Quach, Hang
    Chanan-Khan, Asher A.
    Horvath, Noemi
    Capra, Marcelo
    Ovilla, Roberto
    Jo, Jae-Cheol
    Shin, Ho-Jin
    Thiyagarajah, Piruntha
    Amin, Himal
    Casneuf, Tineke
    Sonneveld, Pieter
    Schecter, Jordan
    Hungria, Vania T. M.
    BLOOD, 2017, 130
  • [47] DARATUMUMAB-BASED COMBINATION THERAPIES IN HEAVILY-PRE-TREATED PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
    Lakshman, A.
    Abeykoon, J.
    Kumar, S.
    Rajkumar, V.
    Kourelis, T.
    Buadi, F.
    Dingli, D.
    Martha, L.
    Gonsalves, W.
    Dispenzieri, A.
    Kyle, R.
    Lin, Y.
    Go, R.
    Warsame, R.
    Hobbs, M.
    Fonder, A.
    Hwa, Y.
    Hayman, S.
    Russell, S.
    Leung, N.
    Gertz, M.
    Kapoor, P.
    HAEMATOLOGICA, 2017, 102 : 508 - 508
  • [48] Efficacy and safety of elranatamab in patients with high-risk relapsed/refractory multiple myeloma (RRMM): A subgroup analysis from MagnetisMM-3
    Larson, Sarah Marie
    Bahlis, Nizar J.
    Maisel, Christopher
    Karlin, Lionel
    Yanovsky, Asya Varshavsky
    Leip, Eric
    Sullivan, Sharon T.
    Viqueira, Andrea
    Touzeau, Cyrille
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma
    Iida, Shinsuke
    Ichinohe, Tatsuo
    Shinagawa, Atsushi
    Suzuki, Kenshi
    Takezako, Naoki
    Aoki, Masayuki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 107 (04) : 460 - 467
  • [50] Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma
    Shinsuke Iida
    Tatsuo Ichinohe
    Atsushi Shinagawa
    Kenshi Suzuki
    Naoki Takezako
    Masayuki Aoki
    International Journal of Hematology, 2018, 107 : 460 - 467
12345